[{"id":"168840e4-a367-4523-bec5-a87bb18a9b81","acronym":"NT-175-201","url":"https://clinicaltrials.gov/study/NCT05877599","created_at":"2023-05-26T15:07:05.809Z","updated_at":"2025-02-25T13:55:14.477Z","phase":"Phase 1","brief_title":"A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation","source_id_and_acronym":"NCT05877599 - NT-175-201","lead_sponsor":"AstraZeneca","biomarkers":" TP53 • HLA-A","pipe":" | ","alterations":" TP53 mutation • HLA-A*02:01","tags":["TP53 • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • NT-175"],"overall_status":"Recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 07/12/2023","start_date":" 07/12/2023","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 08/01/2039","study_completion_date":" 08/01/2039","last_update_posted":"2025-02-20"},{"id":"22763cd5-04a0-4c19-8ce3-8bad45fab6c6","acronym":"CA209-8TX","url":"https://clinicaltrials.gov/study/NCT02960230","created_at":"2021-01-19T13:10:42.375Z","updated_at":"2025-02-25T14:36:49.894Z","phase":"Phase 1/2","brief_title":"H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas","source_id_and_acronym":"NCT02960230 - CA209-8TX","lead_sponsor":"Sabine Mueller, MD, PhD","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02:01 • H3.3K27M • HLA-A*02 positive","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • H3.3K27M • HLA-A*02 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 11/18/2016","start_date":" 11/18/2016","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2025-01-22"},{"id":"49dce72b-9d7c-4760-9f04-db0fc8e432e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06070012","created_at":"2023-10-06T14:11:25.919Z","updated_at":"2025-02-25T16:27:38.972Z","phase":"Phase 2","brief_title":"Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma","source_id_and_acronym":"NCT06070012","lead_sponsor":"Diwakar Davar","biomarkers":" LAG3 • CTLA4","pipe":" | ","alterations":" HLA-A*02:01","tags":["LAG3 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kimmtrak (tebentafusp-tebn)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 01/31/2025","start_date":" 01/31/2025","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2029","study_completion_date":" 11/30/2029","last_update_posted":"2025-01-06"},{"id":"a1bfec25-d893-4cf6-93c8-c3f71ddf2444","acronym":"DURANCE","url":"https://clinicaltrials.gov/study/NCT04106115","created_at":"2021-01-18T20:04:52.084Z","updated_at":"2025-02-25T15:08:49.394Z","phase":"Phase 1/2","brief_title":"DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr","source_id_and_acronym":"NCT04106115 - DURANCE","lead_sponsor":"University College, London","biomarkers":" PD-L1","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • S-588210"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 03/25/2022","start_date":" 03/25/2022","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2029","study_completion_date":" 05/31/2029","last_update_posted":"2024-12-04"},{"id":"45804b31-abb5-4caf-bfa4-174bafa136c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02535078","created_at":"2021-01-18T12:15:32.419Z","updated_at":"2025-02-25T15:06:47.576Z","phase":"Phase 1/2","brief_title":"Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma","source_id_and_acronym":"NCT02535078","lead_sponsor":"Immunocore Ltd","biomarkers":" BRAF • HLA-A","pipe":" | ","alterations":" BRAF mutation • HLA-A*02:01 • HLA-A*02","tags":["BRAF • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • HLA-A*02:01 • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Kimmtrak (tebentafusp-tebn)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 06/19/2023","primary_completion_date":" 06/19/2023","study_txt":" Completion: 09/06/2023","study_completion_date":" 09/06/2023","last_update_posted":"2024-07-24"},{"id":"269bcf7a-a222-4eb1-a733-a5c181aede05","acronym":"SURPASS-3","url":"https://clinicaltrials.gov/study/NCT05601752","created_at":"2022-11-05T15:14:24.529Z","updated_at":"2024-07-02T16:34:25.911Z","phase":"Phase 2","brief_title":"ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)","source_id_and_acronym":"NCT05601752 - SURPASS-3","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • BRCA • PARP1 • MAGEA4","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression","tags":["HLA-A • BRCA • PARP1 • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 08/12/2026","primary_completion_date":" 08/12/2026","study_txt":" Completion: 08/12/2026","study_completion_date":" 08/12/2026","last_update_posted":"2024-06-14"},{"id":"8af52e0c-a6ec-4403-a6fa-b9543bc969cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT06066359","created_at":"2023-10-04T15:10:43.929Z","updated_at":"2024-07-02T16:34:59.118Z","phase":"Phase 1/2","brief_title":"Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma","source_id_and_acronym":"NCT06066359","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 11/30/2023","start_date":" 11/30/2023","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2024-06-04"},{"id":"d5b7efa8-e965-442b-8575-71001ab87e87","acronym":"IGNYTE-ESO","url":"https://clinicaltrials.gov/study/NCT03967223","created_at":"2021-01-19T18:07:33.215Z","updated_at":"2024-07-02T16:35:07.685Z","phase":"Phase 2","brief_title":"Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors","source_id_and_acronym":"NCT03967223 - IGNYTE-ESO","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 08/28/2024","primary_completion_date":" 08/28/2024","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-04-25"},{"id":"b90d0390-a592-4a17-be55-4a843bf4b331","acronym":"","url":"https://clinicaltrials.gov/study/NCT03326921","created_at":"2021-01-29T07:15:51.429Z","updated_at":"2024-07-02T16:35:13.551Z","phase":"Phase 1","brief_title":"HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant","source_id_and_acronym":"NCT03326921","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-A • CD4","pipe":" | ","alterations":" HLA-A*02:01","tags":["HLA-A • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • HA-1 T TCR T Cell Immunotherapy"],"overall_status":"Suspended","enrollment":" Enrollment 24","initiation":"Initiation: 02/23/2018","start_date":" 02/23/2018","primary_txt":" Primary completion: 10/16/2027","primary_completion_date":" 10/16/2027","study_txt":" Completion: 07/16/2028","study_completion_date":" 07/16/2028","last_update_posted":"2024-03-21"},{"id":"aafc6a72-033b-4470-9c1d-5d77ddce9a83","acronym":"","url":"https://clinicaltrials.gov/study/NCT05549921","created_at":"2022-09-22T15:56:31.418Z","updated_at":"2024-07-02T16:35:25.127Z","phase":"Phase 2","brief_title":"Phase II Study of TAEST16001 in Soft Tissue Sarcoma","source_id_and_acronym":"NCT05549921","lead_sponsor":"Sun Yat-sen University","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAEST16001"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 07/08/2022","start_date":" 07/08/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-12-27"},{"id":"cf75cef8-fbca-4f5e-981f-7832552ff034","acronym":"","url":"https://clinicaltrials.gov/study/NCT05993299","created_at":"2023-08-15T19:10:23.528Z","updated_at":"2024-07-02T16:35:33.510Z","phase":"Phase 2","brief_title":"Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma","source_id_and_acronym":"NCT05993299","lead_sponsor":"GlaxoSmithKline","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 10/12/2022","primary_completion_date":" 10/12/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-10-16"},{"id":"02f1ba64-8e85-4daf-b97e-04cf2057733e","acronym":"TEIPP","url":"https://clinicaltrials.gov/study/NCT05898763","created_at":"2023-06-12T15:08:43.704Z","updated_at":"2024-07-02T16:35:37.167Z","phase":"Phase 1/2","brief_title":"TEIPP Immunotherapy in Patients With NSCLC","source_id_and_acronym":"NCT05898763 - TEIPP","lead_sponsor":"Erasmus Medical Center","biomarkers":" CD8","pipe":" | ","alterations":" HLA-A*02:01","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 09/29/2021","start_date":" 09/29/2021","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-09-13"},{"id":"ebcd46a0-c47d-48af-9752-be5c4c9b856b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01176474","created_at":"2021-01-18T04:41:45.709Z","updated_at":"2025-02-25T14:32:13.603Z","phase":"Phase 1","brief_title":"Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma","source_id_and_acronym":"NCT01176474","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CTAG1B","pipe":" | ","alterations":" HLA-A*02:01","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 08/13/2010","start_date":" 08/13/2010","primary_txt":" Primary completion: 08/01/2020","primary_completion_date":" 08/01/2020","study_txt":" Completion: 01/06/2023","study_completion_date":" 01/06/2023","last_update_posted":"2023-07-19"},{"id":"1ef7e3af-6ffd-4b28-a37a-605835973490","acronym":"","url":"https://clinicaltrials.gov/study/NCT01176461","created_at":"2021-01-18T04:41:44.082Z","updated_at":"2025-02-25T14:32:12.851Z","phase":"Phase 1","brief_title":"Multiple Class I Peptides \u0026 Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558","source_id_and_acronym":"NCT01176461","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CTAG1B","pipe":" | ","alterations":" HLA-A*02:01","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 127","initiation":"Initiation: 08/04/2010","start_date":" 08/04/2010","primary_txt":" Primary completion: 12/12/2016","primary_completion_date":" 12/12/2016","study_txt":" Completion: 12/12/2016","study_completion_date":" 12/12/2016","last_update_posted":"2023-01-18"},{"id":"a59f2e7d-773d-4044-b655-2dd3f2f04a4f","acronym":"IMA950-106","url":"https://clinicaltrials.gov/study/NCT03665545","created_at":"2021-01-18T17:59:08.870Z","updated_at":"2024-07-02T16:35:58.554Z","phase":"Phase 1/2","brief_title":"Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma","source_id_and_acronym":"NCT03665545 - IMA950-106","lead_sponsor":"University Hospital, Geneva","biomarkers":" PD-L1","pipe":" | ","alterations":" HLA-A*02:01","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Hiltonol (poly-ICLC) • IMA950"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/25/2018","start_date":" 10/25/2018","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-12-26"},{"id":"4b902844-e9bb-481c-9882-6b4cdce12c83","acronym":"","url":"https://clinicaltrials.gov/study/NCT04878484","created_at":"2021-05-07T11:53:02.821Z","updated_at":"2024-07-02T16:36:04.497Z","phase":"Phase 1","brief_title":"Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT04878484","lead_sponsor":"Athenex, Inc.","biomarkers":" CD8 • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • CTAG1B expression","tags":["CD8 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TCRT-ESO-A2"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/11/2021","start_date":" 08/11/2021","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-09-02"},{"id":"7eecebd3-1e18-42ba-ab0b-e03aa0af1da0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04464889","created_at":"2021-02-24T11:03:04.121Z","updated_at":"2024-07-02T16:36:23.275Z","phase":"Phase 1","brief_title":"HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT04464889","lead_sponsor":"Medigene AG","biomarkers":" CD8 • HLA-A","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • HLA-A2 positive","tags":["CD8 • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • HLA-A2 positive"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/02/2020","start_date":" 07/02/2020","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2021-10-08"},{"id":"3608adc3-d2b1-4e5d-821c-b73096e43b08","acronym":"","url":"https://clinicaltrials.gov/study/NCT00960752","created_at":"2021-01-29T06:59:46.404Z","updated_at":"2024-07-02T16:36:26.379Z","phase":"Phase 2","brief_title":"Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist","source_id_and_acronym":"NCT00960752","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD8 • CD4","pipe":" | ","alterations":" HLA-A*02:01","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 05/20/2010","start_date":" 05/20/2010","primary_txt":" Primary completion: 07/20/2020","primary_completion_date":" 07/20/2020","study_txt":" Completion: 07/20/2020","study_completion_date":" 07/20/2020","last_update_posted":"2021-08-13"},{"id":"046bd970-a819-491c-b309-6d96f8ea30b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03941626","created_at":"2021-01-19T18:01:10.172Z","updated_at":"2024-07-02T16:36:35.027Z","phase":"Phase 1/2","brief_title":"Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies","source_id_and_acronym":"NCT03941626","lead_sponsor":"Shenzhen BinDeBio Ltd.","biomarkers":" HLA-A • MSLN • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • MSLN positive • HLA-A positive","tags":["HLA-A • MSLN • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • MSLN positive • HLA-A positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • multi-target gene-modified CAR-T/TCR-T cell immunotherapy"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2021-02-04"},{"id":"00da83e2-9529-4a06-b56a-70a4c9d0b96b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00022334","created_at":"2022-04-24T09:53:53.151Z","updated_at":"2024-07-02T16:36:42.413Z","phase":"Phase 1/2","brief_title":"Vaccine Therapy in Treating Patients With Liver Cancer","source_id_and_acronym":"NCT00022334","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" AFP","pipe":" | ","alterations":" HLA-A*02:01","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 01/01/2001","start_date":" 01/01/2001","primary_txt":" Primary completion: 12/01/2004","primary_completion_date":" 12/01/2004","study_txt":" Completion: 10/01/2008","study_completion_date":" 10/01/2008","last_update_posted":"2020-08-03"},{"id":"22c63490-439d-4ff9-841c-25cdfa21ee1d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00090896","created_at":"2021-01-18T00:16:29.185Z","updated_at":"2024-07-02T16:36:42.439Z","phase":"Phase 1","brief_title":"CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery","source_id_and_acronym":"NCT00090896","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" HLA-A • CTLA4","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A positive","tags":["HLA-A • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 04/01/2004","start_date":" 04/01/2004","primary_txt":" Primary completion: 07/01/2008","primary_completion_date":" 07/01/2008","study_txt":" Completion: 10/01/2009","study_completion_date":" 10/01/2009","last_update_posted":"2020-08-03"},{"id":"031439da-5f9c-460c-8c05-2a1c5a400206","acronym":"","url":"https://clinicaltrials.gov/study/NCT03638206","created_at":"2021-01-18T17:51:53.397Z","updated_at":"2024-07-02T16:36:52.614Z","phase":"Phase 1/2","brief_title":"Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies","source_id_and_acronym":"NCT03638206","lead_sponsor":"Shenzhen BinDeBio Ltd.","biomarkers":" MET • CD19 • HLA-A • MSLN • CD22 • CD33 • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • CD19 expression • HLA-A positive","tags":["MET • CD19 • HLA-A • MSLN • CD22 • CD33 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • CD19 expression • HLA-A positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CAR-T cell immunotherapy • multi-target gene-modified CAR-T/TCR-T cell immunotherapy"],"overall_status":"Recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2019-12-11"},{"id":"11bb818d-40e6-4fec-af67-e5c9e6902773","acronym":"","url":"https://clinicaltrials.gov/study/NCT02550535","created_at":"2021-02-01T11:52:52.801Z","updated_at":"2024-07-02T16:37:06.491Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS \u0026 AML Patients","source_id_and_acronym":"NCT02550535","lead_sponsor":"Cell Medica Ltd","biomarkers":" WT1","pipe":" | ","alterations":" HLA-A*02:01","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CMD-602"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 05/01/2018","primary_completion_date":" 05/01/2018","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2018-10-02"},{"id":"17719ddc-bb4f-436a-93d2-9229a493717f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01334060","created_at":"2021-02-01T11:52:26.190Z","updated_at":"2024-07-02T16:37:07.124Z","phase":"Phase 2","brief_title":"WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation","source_id_and_acronym":"NCT01334060","lead_sponsor":"University Hospital Southampton NHS Foundation Trust","biomarkers":" ABL1 • BCR • WT1","pipe":" | ","alterations":" HLA-A*02:01","tags":["ABL1 • BCR • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e p.DOM-WT1-126 DNA vaccine"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 02/01/2011","start_date":" 02/01/2011","primary_txt":" Primary completion: 02/01/2013","primary_completion_date":" 02/01/2013","study_txt":" Completion: 02/26/2013","study_completion_date":" 02/26/2013","last_update_posted":"2018-09-07"}]